caa a22 4500 465735088 CHVBK 20180323111752.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00167063 doi (NATIONALLICENCE)springer-10.1007/BF00167063 Low dose rate radiotherapy for transplantable gliosarcoma in the rat brain [Elektronische Daten] [Jae Kim, Alan Alfieri, Mark Rosenblum, Sergio Bravo, Sang Kim] Summary: Interstitial brachytherapy with low energy radionuclides is becoming widely used in conjunction with external beam radiotherapy in the treatment of primary malignant gliomas of the brain. Few radiobiological studies have been carried out with low dose rate brachytherapy for brain tumors. Since we have recently developed a non-invasive low dose rate radiotherapy model for the treatment of transplantable 9L gliosarcoma growing in the rat brain, we carried out a series of radiobiological studies to determine the dose rate effect on the tumor and normal brain tissue. Using TCD50 (the radiation dose to control 50% tumor control) as the endpoints, we obtained the results indicating that the tumor control rate was highly dependent on the dose rate and the total dose delivered to the tumor. The TCD50 of dose rates ranging from 100 cGy/min, 120 cGy/hr, and 40 cGy/hr were 25 Gy, 80 Gy, and 100 Gy, respectively. The normal tissue effects were most pronounced with high dose rate irradiation (100 cGy/min). The LD50 for high dose rate irradiation to the whole brain was 29 Gy. In contrast, the majority of animals treated with low dose rate radio-therapy behaved quite normal up to a year follow-up. The late histopathological changes of the irradiated brain usually consisted of vascular and white matter necrosis, although the extent of such changes showed a considerable individual variation within the long-term survivors. Kluwer Academic Publishers, 1990 low dose rate radiotherapy nationallicence experimental tumors nationallicence Kim Jae Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA aut Alfieri Alan Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA aut Rosenblum Mark Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Bravo Sergio Department of Radiotherapy, University of Chile, Santiago, Chile aut Kim Sang Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 9/1(1990-08-01), 9-15 0167-594X 9:1<9 1990 9 11060 https://doi.org/10.1007/BF00167063 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00167063 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kim Jae Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA aut NATIONALLICENCE 700 1- Alfieri Alan Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA aut NATIONALLICENCE 700 1- Rosenblum Mark Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 700 1- Bravo Sergio Department of Radiotherapy, University of Chile, Santiago, Chile aut NATIONALLICENCE 700 1- Kim Sang Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 9/1(1990-08-01), 9-15 0167-594X 9:1<9 1990 9 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer